Patents Examined by Rita Mitra
-
Patent number: 7223730Abstract: This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof.Type: GrantFiled: August 23, 2001Date of Patent: May 29, 2007Assignee: Hefei-Siu-Fung USTC Pharmaceutical Co., Ltd.Inventors: Chun Wang, Benjamin Xy Li, Xin Cheng, Jing Liu, Li-Wen Niu, Wan-Zhi Huang, Zhen-Yu Xu, Dan Luo, Lian-Di Kang, Jin-Guo Ding, Fang Rong, Yan Liu, Hui-Ran Chen
-
Patent number: 7186795Abstract: Disclosed is a gene encoding a mutated lactoferricin peptide and an E. coli cell transformed with the same, wherein the mutated lactoferricin peptide has substitutions at the 7th and 10th amino acid residues of the wildtype bovine lactoferricin. The gene of the present invention can be expressed in E. coli at high efficiency, and the expressed mutated lactoferricin peptide can be purified at high yield, thus making its mass production possible.Type: GrantFiled: November 30, 2002Date of Patent: March 6, 2007Assignee: Easy Bio System, Inc.Inventors: Ha-Kun Kim, Dae-Kyung Kang, Ju-Hoon Lee
-
Patent number: 7173007Abstract: The disclosure provides a novel class of cationic cathelin-like peptides and polypeptides that have antimicrobial activity. These peptides are useful for inhibiting microbial infection or growth.Type: GrantFiled: March 31, 2004Date of Patent: February 6, 2007Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veteran AffairsInventors: Mohamed Zaiou, Richard L. Gallo, Victor Nizet
-
Patent number: 7166291Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can fI or Can fII. are disclosed. A cDNA encoding a peptide having a Can fI activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can fII activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can fI or Can fII nucleic acid in a sample or for the recombinant production of petides having a Can fI or Can fII activity. Peptides having a Can fI or Can fII activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: GrantFiled: August 12, 2005Date of Patent: January 23, 2007Assignee: Heska CorporationInventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
-
Patent number: 7153670Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.Type: GrantFiled: October 8, 2004Date of Patent: December 26, 2006Assignees: Human Genome Sciences, Inc., The American Red CrossInventors: Gregg A. Hastings, Gene Liau, Elena Tsifrina
-
Patent number: 7125848Abstract: A method is provided for using Cav2.2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.Type: GrantFiled: June 10, 2004Date of Patent: October 24, 2006Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Matthew Oliver Fraser, Steven B. Landau, Edward C. Burgard
-
Patent number: 7122346Abstract: A process is described for the recombinant production of ribonucleoproteins in prokaryotic cells.Type: GrantFiled: November 6, 2002Date of Patent: October 17, 2006Assignee: F. Hoffmann-La Roche AGInventors: Jean Burckhardt, Michael Haass, Hans-Peter Lehmann
-
Patent number: 7119166Abstract: A universal folding method that has been demonstrated to be effective in refolding a variety of very different proteins expressed in bacteria as inclusion bodies has been developed. Representative proteins that can be dissolved and refolded in biologically active form, with the native structure, are shown in Table I. The method has two key steps to unfold and then refold the proteins expressed in the inclusion bodies. The first step is to raise the pH of the protein solution in the presence of denaturing agents to pH greater than 9, preferably 10. The protein solution may be maintained at the elevated pH for a period of up to about 24 hours, or the pH immediately decreased slowly, in increments of about 0.2 pH units/24 hours, until the solution reaches a pH of about 8.0, or both steps used. In the preferred embodiment, purified inclusion bodies are dissolved in 8 M urea, 0.1 M Tris, 1 mM glycine, 1 mM EDTA, 10 mM beta-mercaptoethanol, 10 mM dithiothreitol (DTT), 1 mM reduced glutathione (GSH), 0.Type: GrantFiled: April 17, 2003Date of Patent: October 10, 2006Assignee: Oklahoma Medical Research FoundationInventor: Xinli Lin
-
Patent number: 7087722Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.Type: GrantFiled: January 27, 2000Date of Patent: August 8, 2006Assignee: Savient Pharmaceuticals, Inc.Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
-
Patent number: 7049403Abstract: The present invention relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt, (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.Type: GrantFiled: April 20, 2001Date of Patent: May 23, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuaki Itoh, Nobuhiro Suzuki, Kazunori Nishi, Hideki Kizawa, Masataka Harada, Kazuhiro Ogi
-
Patent number: 7041782Abstract: The invention is directed to purified and isolated novel ss3939 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: June 22, 2001Date of Patent: May 9, 2006Assignee: Immunex CorporationInventor: Dirk M. Anderson
-
Patent number: 7034135Abstract: Novel NBS-2, NBS-3, PYRIN-12/NBS-4, and NBS-5 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated NBS-2, NBS-3, PYRIN-12/NBS-4, and NBS-5 proteins, the invention further provides NBS-2, NBS-3, PYRIN-12/NBS-4, and NBS-5 fusion proteins, antigenic peptides and anti-NBS-2, anti-NBS-3, anti-PYRIN-12/NBS-4, and anti-NBS-5 antibodies. The invention also provides NBS-2, NBS-3, PYRIN-12/NBS-4, and NBS-5 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a NBS-2, NBS-3, PYRIN-12/NBS-4, or NBS-5 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: April 4, 2002Date of Patent: April 25, 2006Assignees: Millennium Pharmaceuticals, Inc., WyethInventors: John Bertin, Weiye Wang, Maria Blatcher
-
Patent number: 7026293Abstract: The present invention provides a pharmaceutical composition and a method for reducing an infarct region resulting from the ischemic necrosis of cells, especially, a pharmaceutical composition and a method for suppressing ischemia-reperfusion injury in the treatment of ischemic heart disease. The pharmaceutical composition and the method utilize a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has the effect of reducing an infarct region. The substance is preferably a natriuretic peptide. The present invention is particularly useful for the treatment or prophylaxis of ischemic disease.Type: GrantFiled: January 3, 2001Date of Patent: April 11, 2006Assignee: Daiichi Suntory Pharma Co., Ltd.Inventor: Masafumi Kitakaze
-
Patent number: 7026128Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: GrantFiled: July 16, 2002Date of Patent: April 11, 2006Assignee: Heska CorporationInventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
-
Patent number: 7022672Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.Type: GrantFiled: November 30, 2001Date of Patent: April 4, 2006Assignees: Chiron Corporation, G. D. Searle, LLCInventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rejsharan K. Bana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
-
Patent number: 7001881Abstract: The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.Type: GrantFiled: April 24, 2000Date of Patent: February 21, 2006Assignee: Rhode Island HospitalInventor: Gregory D. Jay
-
Patent number: 6987178Abstract: The present invention relates to methods and compositions for the treatment of biological disorders regulatable by the controlled expression or inhibition of the described uncoupling proteins (UCPs).Type: GrantFiled: June 7, 2002Date of Patent: January 17, 2006Assignee: Lexicon Genetics IncorporatedInventors: C. Alexander Turner, Jr., Brian Mathur, Brian Zambrowicz, Arthur T. Sands
-
Patent number: 6977160Abstract: The object of the present invention is to utilize, as a sensor protein, a molecular recognizing ability of a protein that scarcely undergoes any structural change by the binding of a target substance. According to the present invention, there is provided a sensor protein comprising an insert-type fusion protein composed of a reporter protein and a biding protein wherein said binding protein is inserted into the amino acid sequence of said reporter protein.Type: GrantFiled: May 11, 2001Date of Patent: December 20, 2005Assignee: Mitsubishi Chemical CorporationInventors: Hiroshi Yanagawa, Nobuhide Doi, Naoto Nemoto
-
Patent number: 6967246Abstract: A novel microbial protein is described which appears to have significant homology to plant expansin proteins and has the ability to weaken filter paper and swell cellulose. A DNA is described which encodes the novel protein.Type: GrantFiled: July 17, 2002Date of Patent: November 22, 2005Assignee: Genencor International, Inc.Inventors: Barbara A. Swanson, Michael Ward, Merja Penttilä , Jaakko Pere, Markku Saloheimo
-
Patent number: 6967245Abstract: The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: GrantFiled: October 15, 2002Date of Patent: November 22, 2005Assignee: Genentech, Inc.Inventors: Sean Adams, James Pan